Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 21507571)


The taccalonolides, novel microtubule stabilizers, and γ-radiation have additive effects on cellular viability.

Risinger AL, Natarajan M, Thomas CR Jr, Mooberry SL.

Cancer Lett. 2011 Aug 1;307(1):104-11. doi: 10.1016/j.canlet.2011.03.022. Epub 2011 Apr 19.


Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.

Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC Jr, Hemscheidt TK, Mooberry SL.

Cancer Res. 2003 Jun 15;63(12):3211-20.


Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers.

Li J, Risinger AL, Peng J, Chen Z, Hu L, Mooberry SL.

J Am Chem Soc. 2011 Nov 30;133(47):19064-7. doi: 10.1021/ja209045k. Epub 2011 Nov 8.


Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Risinger AL, Li J, Bennett MJ, Rohena CC, Peng J, Schriemer DC, Mooberry SL.

Cancer Res. 2013 Nov 15;73(22):6780-92. doi: 10.1158/0008-5472.CAN-13-1346. Epub 2013 Sep 18.


Identification and biological activities of new taccalonolide microtubule stabilizers.

Peng J, Risinger AL, Fest GA, Jackson EM, Helms G, Polin LA, Mooberry SL.

J Med Chem. 2011 Sep 8;54(17):6117-24. doi: 10.1021/jm200757g. Epub 2011 Aug 11.


Taccalonolides: Novel microtubule stabilizers with clinical potential.

Risinger AL, Mooberry SL.

Cancer Lett. 2010 May 1;291(1):14-9. doi: 10.1016/j.canlet.2009.09.020. Epub 2009 Oct 31. Review.


Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel.

Risinger AL, Mooberry SL.

Cell Cycle. 2011 Jul 1;10(13):2162-71. Epub 2011 Jul 1.


Taccalonolide microtubule stabilizers.

Li J, Risinger AL, Mooberry SL.

Bioorg Med Chem. 2014 Sep 15;22(18):5091-6. doi: 10.1016/j.bmc.2014.01.012. Epub 2014 Jan 15. Review.


Synthetic reactions with rare taccalonolides reveal the value of C-22,23 epoxidation for microtubule stabilizing potency.

Peng J, Risinger AL, Li J, Mooberry SL.

J Med Chem. 2014 Jul 24;57(14):6141-9. doi: 10.1021/jm500619j. Epub 2014 Jul 2.


The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.

Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Ludueña RF, Kruh GD, Mooberry SL.

Cancer Res. 2008 Nov 1;68(21):8881-8. doi: 10.1158/0008-5472.CAN-08-2037.


The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation.

Risinger AL, Riffle SM, Lopus M, Jordan MA, Wilson L, Mooberry SL.

Mol Cancer. 2014 Feb 28;13:41. doi: 10.1186/1476-4598-13-41.


Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.

Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH, Polverini PJ.

Mol Cancer Ther. 2008 Jul;7(7):2060-9. doi: 10.1158/1535-7163.MCT-08-0287.


Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).

Pradier O, Rave-Fränk M, Schmidberger H, Bömecke M, Lehmann J, Meden H, Hess CF.

J Cancer Res Clin Oncol. 1999;125(1):20-7.


13-cis retinoic acid in combination with interferon-alpha enhances radiation sensitivity of human squamous cell carcinoma cells of the oral cavity.

Bläse M, Zaruba MM, Santo-Hoeltje L, Bamberg M, Hoffmann W, Rodemann HP.

Strahlenther Onkol. 1999 Nov;175(11):563-8.


Hydrolysis reactions of the taccalonolides reveal structure-activity relationships.

Li J, Peng J, Risinger AL, Mooberry SL.

J Nat Prod. 2013 Jul 26;76(7):1369-75. doi: 10.1021/np400435t. Epub 2013 Jul 15.


Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.

Rathinasamy K, Jindal B, Asthana J, Singh P, Balaji PV, Panda D.

BMC Cancer. 2010 May 19;10:213. doi: 10.1186/1471-2407-10-213.


Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.

Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M.

Oral Oncol. 2004 Aug;40(7):713-9.


The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.

Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L.

Mol Cancer Ther. 2005 Jul;4(7):1086-95.


Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells.

Wu X, Sooman L, Lennartsson J, Bergström S, Bergqvist M, Gullbo J, Ekman S.

Int J Oncol. 2013 Jan;42(1):297-304. doi: 10.3892/ijo.2012.1710. Epub 2012 Nov 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk